Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Tang

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
JCI Insight|December 22, 2025
Identification of Ephrin type-B receptor 4 as a critical mediator of tissue fibrosisBrian Wu, Starlee S Lively, Shabana Vohra, et al.
Pancreas|June 14, 2017
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine TumorsJonathan R Strosberg, Thorvardur R Halfdanarson, Andrew M Bellizzi, et al.
Cancer Immunology Research|March 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 CytokinesMari Nakazawa, Soren Charmsaz, Elsa Hallab, et al.
The American Journal of Surgical Pathology|February 8, 2014
Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 casesOlca Basturk, Laura Tang, Ralph H Hruban, et al.
Cancer Immunology Research|June 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumorsHoward L Li, Soren Charmsaz, Chester Kao, et al.
Nature Communications|January 7, 2023
Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancersWalid K Chatila, Henry Walch, Jaclyn F Hechtman, et al.
Journal for Immunotherapy of Cancer|April 21, 2026
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinomaHoward L Li, Soren Charmsaz, Benjamin J Reisman, et al.
Nature Communications|April 21, 2025
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitorsChester Kao, Soren Charmsaz, Hua-Ling Tsai, et al.
Journal for Immunotherapy of Cancer|January 20, 2025
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockadeStephanie L Alden, Soren Charmsaz, Howard L Li, et al.
Communications Biology|November 26, 2021
Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancerSuhasini Joshi, Erica DaGama Gomes, Tai Wang, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
JCI Insight|December 22, 2025
Identification of Ephrin type-B receptor 4 as a critical mediator of tissue fibrosisBrian Wu, Starlee S Lively, Shabana Vohra, et al.
Pancreas|June 14, 2017
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine TumorsJonathan R Strosberg, Thorvardur R Halfdanarson, Andrew M Bellizzi, et al.
Cancer Immunology Research|March 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 CytokinesMari Nakazawa, Soren Charmsaz, Elsa Hallab, et al.
The American Journal of Surgical Pathology|February 8, 2014
Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 casesOlca Basturk, Laura Tang, Ralph H Hruban, et al.
Cancer Immunology Research|June 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumorsHoward L Li, Soren Charmsaz, Chester Kao, et al.
Nature Communications|January 7, 2023
Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancersWalid K Chatila, Henry Walch, Jaclyn F Hechtman, et al.
Journal for Immunotherapy of Cancer|April 21, 2026
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinomaHoward L Li, Soren Charmsaz, Benjamin J Reisman, et al.
Nature Communications|April 21, 2025
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitorsChester Kao, Soren Charmsaz, Hua-Ling Tsai, et al.
Journal for Immunotherapy of Cancer|January 20, 2025
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockadeStephanie L Alden, Soren Charmsaz, Howard L Li, et al.
Communications Biology|November 26, 2021
Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancerSuhasini Joshi, Erica DaGama Gomes, Tai Wang, et al.
Pageof 10